At GB Sciences, we have two equally important constituencies–the patients who need what we do, and the investors that support what we do. Without the latter, we could not help the former.

We continue to explore the leading edge of biomedical research for the development of cannabis-based therapies for the benefit of both constituencies.

We encourage investors to read our press releases and public filings. Questions can be emailed to our CFO, Zach Swarts, at zach@gbsciences.com – and welcome aboard!